Press Release: Novartis receives FDA approval for -2-

References

1. Itvisma(R) (onasemnogene abeparvovec-brve). Prescribing Information.

Novartis Gene Therapies, Inc.

2. Proud C, et al. Neuromuscul Disord. 2025;(53):0960-8966.

3. Clinicaltrials.Gov. STRENGTH Study Results.

https://clinicaltrials.gov/study/NCT05386680. Accessed November 2025.

4. Anderton RS and Mastaglia FL. Expert Rev Neurother.

2015;15(8):895--908.

5. National Organization for Rare Disorders (NORD). Spinal Muscular Atrophy.

https://rarediseases.org/rare-diseases/spinal-muscular-atrophy/. Accessed

November 2025.

6. Lorson CL, et al. Hum Mol Genet. 2010;(15):111-8.

7. Cure SMA. State of SMA 2024 Report.

https://www.curesma.org/wp-content/uploads/2025/04/State-of-SMA-Report2024_vWeb-4.pdf.

Accessed November 2025.

8. Cure SMA. Address the Unmet Needs of Children and Adults with Spinal

Muscular Atrophy.

https://www.curesma.org/wp-content/uploads/2024/08/NIH_SMA_Research_FactSheet.pdf.

Accessed November 2025.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

November 24, 2025 17:16 ET (22:16 GMT)